A phase 3 trial of Durasert 3-year treatment for posterior segment uveitis showed a significant reduction in uveitis recurrence at 12 months, according to a press release from pSivida.
The study, which examined 153 patients with posterior segment uveitis, found 36.6% of patients treated with Durasert had a recurrence while 71.2% of those in the sham group experienced a recurrence. The trial previously showed a significant reduction in the recurrence of posterior segment uveitis through 6 months of treatment.
“We continue to receive highly positive feedback from specialists regarding
Uncategorized